共 35 条
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
被引:9
作者:
Li, Zheng
[1
,2
]
Wang, Jun
[1
,2
]
Ge, Shuai-Shuai
[1
,2
]
Qiu, Qiao-Cheng
[1
,2
]
Du, Jia-Hui
[3
]
Shan, Shuang-Shuang
[3
]
Shen, Xiang-Dong
[1
,2
]
Wan, Chao-Ling
[1
,2
]
Wang, Bin-Ru
[1
,2
]
Wu, De-Pei
[1
,2
]
Qiu, Hui-Ying
[1
,2
]
Xue, Sheng-Li
[1
,2
]
机构:
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou, Peoples R China
[3] Suzhou Vocat Hlth Coll, Suzhou Key Lab Med Biotechnol, Suzhou, Peoples R China
基金:
中国国家自然科学基金;
关键词:
venetoclax;
azacitidine;
midostaurin;
t(8;
21);
relapsed acute myeloid leukemia;
KIT mutation;
targeted therapy;
MUTATIONS;
CANCER;
ADULTS;
D O I:
10.3389/fonc.2022.841276
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhibitor. The venetoclax+HMA strategy is also a notable salvage regimen that achieves good clinical outcomes in the treatment of relapsed or refractory (R/R) AML. However, in our clinical practice, we found that disease progressed rapidly even after venetoclax+azacitidine (AZA) therapy in two relapsed t(8;21) AML patients with KIT mutations. We report for the first time the therapeutic potential of venetoclax+midostaurin as a new combination therapy for relapsed t(8;21) AMLs with KIT mutations showing resistance to venetoclax+AZA therapy. Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. Our study shows that the venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations.
引用
收藏
页数:6
相关论文
共 35 条